IBO Stock Overview
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Universal Ibogaine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.02 |
| 52 Week High | CA$0.03 |
| 52 Week Low | CA$0.005 |
| Beta | 4.6 |
| 1 Month Change | -20.00% |
| 3 Month Change | 300.00% |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBO | CA Healthcare | CA Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.0% |
| 1Y | 0% | 0.8% | 3.2% |
Return vs Industry: IBO matched the Canadian Healthcare industry which returned 0.3% over the past year.
Return vs Market: IBO underperformed the Canadian Market which returned 3.9% over the past year.
Price Volatility
| IBO volatility | |
|---|---|
| IBO Average Weekly Movement | 54.5% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: IBO's share price has been volatile over the past 3 months.
Volatility Over Time: IBO's weekly volatility has decreased from 66% to 54% over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nick Karos | universalibogaine.com |
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.
Universal Ibogaine Inc. Fundamentals Summary
| IBO fundamental statistics | |
|---|---|
| Market cap | CA$5.82m |
| Earnings (TTM) | -CA$1.19m |
| Revenue (TTM) | CA$2.22m |
2.6x
P/S Ratio-4.9x
P/E RatioIs IBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBO income statement (TTM) | |
|---|---|
| Revenue | CA$2.22m |
| Cost of Revenue | CA$1.58m |
| Gross Profit | CA$640.33k |
| Other Expenses | CA$1.83m |
| Earnings | -CA$1.19m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0041 |
| Gross Margin | 28.79% |
| Net Profit Margin | -53.30% |
| Debt/Equity Ratio | 153.6% |
How did IBO perform over the long term?
See historical performance and comparison